Evidence map›Paper›PMID 32853222›Full record

SynthesisPloS one2020

Individual response to antidepressants for depression in adults-a meta-analysis and simulation study.

Klaus Munkholm, Stephanie Winkelbeiner, Philipp Homan

Registry-linked trialAbstract readMeta-Analysis
In one paragraph

Synthesis in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06856161 (A Novel Blood Test as a Differential Diagnosis and Drug Efficacy Biomarker in Mental Health), which is not on this map. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06856161 recruitingnot on this mapstarted 2025, after this paper: background citation

A Novel Blood Test as a Differential Diagnosis and Drug Efficacy Biomarker in Mental Health

TypeobservationalSponsorFraser HealthRan2025 to 2027Enrolled500ConditionsDepression - Major Depressive Disorder, Schizophenia Disorder, Psychosis, Mania (Neurotic)
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Reappraising the variability of effects of antipsychotic medication in schizophrenia: a meta-analysis.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2022
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Klaus MunkholmNordic Cochrane Centre, Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0001-6437-0359
Stephanie WinkelbeinerPsychiatric University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Philipp HomanPsychiatric University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-9034-148X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe observation that some patients appear to respond better to antidepressants for depression than others encourages the assumption that the effect of antidepressants differs between individuals and that treatment can be personalized.

objectiveTo compare the outcome variance in patients receiving antidepressants with the outcome variance in patients receiving placebo in randomized controlled trials (RCTs) of adults with major depressive disorder (MDD) and to illustrate, using simulated data, components of variation of RCTs.

methodsFrom a dataset comprising 522 RCTs of antidepressants for adult MDD, we selected the placebo-controlled RCTs reporting outcomes on the 17 or 21 item Hamilton Depression Rating Scale or the Montgomery-Asberg Depression Rating Scale and extracted the means and SDs of raw endpoint scores or baseline to endpoint changes scores on eligible depression symptom rating scales. We conducted inverse variance random-effects meta-analysis with the variability ratio (VR), the ratio between the outcome variance in the group of patients receiving antidepressants and the outcome variance in the group receiving placebo, as the primary outcome. An increased variance in the antidepressant group would indicate individual differences in response to antidepressants.

resultsWe analysed 222 RCTs that investigated 19 different antidepressants compared with placebo in 345 comparisons, comprising a total of 61144 adults with an MDD diagnosis. Across all comparisons, the VR for raw endpoint scores was 0.98 (95% CI 0.96 to 1.00, I2 = 0%) and 1.00 (95% CI 0.99 to 1.02, I2 = 0%) for baseline-to-endpoint change scores.

conclusionBased on these data, we cannot reject the null hypothesis of equal variances in the antidepressant group and the placebo group. Given that RCTs cannot provide direct evidence for individual treatment effects, it may be most reasonable to assume that the average effect of antidepressants applies also to the individual patient.

Indexed as

Antidepressive AgentsDepressionHumansRandomized Controlled Trials as TopicTreatment OutcomeAntidepressive Agents

Identifiers

PMID32853222
PMCPMC7451660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.